Results 41 to 50 of about 14,154 (120)

Thymic Involution and Function in People With HIV and General Population Controls: A Cross‐Sectional Analysis From Two Danish Cohort Studies

open access: yesAging Cell, Volume 25, Issue 10, October 2026.
Thymic involution, the age‐related replacement of thymic soft tissue by fat, has been linked to immunosenescence and chronic inflammation. Whether HIV infection affects thymic involution remains unclear. We found that people with HIV on long‐term antiretroviral therapy had more thymic tissue than controls, indicating less thymic involution. More thymic
Manon C. Vanbellinghen   +15 more
wiley   +1 more source

UltRaSoUnd‐guided evaLuAtion of metabolic health in a cohort of midlife women with HIV: The URSULA study

open access: yesHIV Medicine, Volume 27, Issue 10, Page 1650-1662, October 2026.
Abstract Objectives We aimed to determine the prevalence of metabolic disorders, liver steatosis and metabolic dysfunction‐associated steatotic liver disease (MASLD) in a cohort of middle‐aged women with HIV (WoWH) and to explore associations between liver steatosis, visceral fat depots and carotid atherosclerosis.
Mariacristina Poliseno   +13 more
wiley   +1 more source

Comparison of long-term treatment with one of two NRTI-containing regimens versus an NRTI-sparing regimen for first-line HIV therapy as measured by continuous therapeutic drug monitoring over a 96 week period

open access: yes, 2010
Eine klassische HIV-Primärtherapie setzt sich aus einer Kombination von zwei Nukleosidischen Reverse-Transkriptase-Inhibitoren (NRTI) mit Protease-Inhibitoren (PI) oder Nicht-Nukleosidischen Reverse-Transkriptase-Inhibitoren (NNRTI) zusammen.
Drechsel, F. Philipp
core   +2 more sources

NRTI mutations, including summary of proportion with thymidine analogue mutations (TAMs).

open access: yes, 2013
NRTI mutations, including summary of proportion with thymidine analogue mutations (TAMs).
Nuala McGrath (230042)   +6 more
core   +1 more source

The comparative effectiveness of NRTI-sparing dual regimens in emulated trials using observational data from the Swiss HIV Cohort Study [PDF]

open access: yes, 2018
BACKGROUND Nucleoside (or nucleotide) reverse transcriptase inhibitors (NRTIs) cause side effects in some patients, prompting the use of either partly or fully NRTI-sparing regimens. METHODS We used data from the Swiss HIV Cohort Study to estimate the
Swiss HIV Cohort Study   +41 more
core   +1 more source

Health transitions in HIV-seropositive individulas undergoing NRTI-based and NRTI-sparing treatment strategies.

open access: yes, 2015
NRTI-sparing strategies are often prescribed to reduce the impact of drug toxicities on age related co-morbidities, particularly relevant in frail individuals.
STENTARELLI, Chiara   +4 more
core  

Prevalence of major NRTI and NNRTI resistance mutations in individuals with transmitted drug resistance.

open access: yes, 2016
Absolute and cumulative prevalence of each major nucleoside (NRTI) and nonnucleoside RT Inhibitor (NNRTI) drug-resistance mutation (DRM) in individuals with intermediate or high-level transmitted NRTI or NNRTI resistance from a meta-analysis of 287 ...
Neil Parkin (273844)   +31 more
core   +1 more source

Distribution of NRTI (a) and NNRTI (b) resistance-associated mutations detected in the historical genotypic resistance tests of the patients.

open access: yes, 2015
NNRTI: non nucleoside reverse transcriptase inhibitors, NRTI: nucleoside reverse transcriptase inhibitors.
Benoit Visseaux (288245)   +10 more
core   +1 more source

Nucleoside/tide Reverse Transcriptase Inhibitor (NRTI) mutation profiles.

open access: yes, 2014
Nucleoside/tide Reverse Transcriptase Inhibitor (NRTI) mutation profiles associated with failure to d4T- or ABC -based regimens are depicted in white and grey respectively. The numbers represent percentages.
Irene Ketseoglou (562194)   +6 more
core   +1 more source

Drug resistance mutations to NRTI, NNRTI and PI according to the HIV-1 subtypes and resistance profile.

open access: yes, 2019
Drug resistance mutations to NRTI, NNRTI and PI according to the HIV-1 subtypes and resistance profile.
Marinela Mirandela (8044202)   +8 more
core   +1 more source

Home - About - Disclaimer - Privacy